Suppr超能文献

猴免疫缺陷病毒阻断 ART 后病毒学和免疫学特征

Virologic and Immunologic Features of Simian Immunodeficiency Virus Control Post-ART Interruption in Rhesus Macaques.

机构信息

Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.

Centre de recherche du CHUM, Montreal, Quebec, Canada.

出版信息

J Virol. 2020 Jul 1;94(14). doi: 10.1128/JVI.00338-20.

Abstract

Antiretroviral therapy (ART) cannot eradicate human immunodeficiency virus (HIV) and a rapid rebound of virus replication follows analytical treatment interruption (ATI) in the vast majority of HIV-infected individuals. Sustained control of HIV replication without ART has been documented in a subset of individuals, defined as posttreatment controllers (PTCs). The key determinants of post-ART viral control remain largely unclear. Here, we identified 7 SIV-infected rhesus macaques (RMs), defined as PTCs, who started ART 8 weeks postinfection, continued ART for >7 months, and controlled plasma viremia at <10 copies/ml for up to 8 months after ATI and <200 copies/ml at the latest time point. We characterized immunologic and virologic features associated with post-ART SIV control in blood, lymph node (LN), and colorectal (RB) biopsy samples compared to 15 noncontroller (NC) RMs. Before ART initiation, PTCs had higher CD4 T cell counts, lower plasma viremia, and SIV-DNA content in blood and LN compared to NCs, but had similar CD8 T cell function. While levels of intestinal CD4 T cells were similar, PTCs had higher frequencies of Th17 cells. On ART, PTCs had significantly lower levels of residual plasma viremia and SIV-DNA content in blood and tissues. After ATI, SIV-DNA content rapidly increased in NCs, while it remained stable or even decreased in PTCs. Finally, PTCs showed immunologic benefits of viral control after ATI, including higher CD4 T cell levels and reduced immune activation. Overall, lower plasma viremia, reduced cell-associated SIV-DNA, and preserved Th17 homeostasis, including at pre-ART, are the main features associated with sustained viral control after ATI in SIV-infected RMs. While effective, antiretroviral therapy is not a cure for HIV infection. Therefore, there is great interest in achieving viral remission in the absence of antiretroviral therapy. Posttreatment controllers represent a small subset of individuals who are able to control HIV after cessation of antiretroviral therapy, but characteristics associated with these individuals have been largely limited to peripheral blood analysis. Here, we identified 7 SIV-infected rhesus macaques that mirrored the human posttreatment controller phenotype and performed immunologic and virologic analysis of blood, lymph node, and colorectal biopsy samples to further understand the characteristics that distinguish them from noncontrollers. Lower viral burden and preservation of immune homeostasis, including intestinal Th17 cells, both before and after ART, were shown to be two major factors associated with the ability to achieve posttreatment control. Overall, these results move the field further toward understanding of important characteristics of viral control in the absence of antiretroviral therapy.

摘要

抗逆转录病毒疗法(ART)无法根除人类免疫缺陷病毒(HIV),并且在绝大多数 HIV 感染个体中,分析性治疗中断(ATI)后病毒复制会迅速反弹。在一小部分个体中已经记录到了 HIV 复制的持续控制,这些个体被定义为治疗后控制者(PTC)。ART 后病毒控制的关键决定因素在很大程度上仍不清楚。在这里,我们鉴定了 7 只感染 SIV 的恒河猴(RMs),它们被定义为 PTC,在感染后 8 周开始接受 ART,持续接受 ART 超过 7 个月,并在 ATI 后长达 8 个月内将血浆病毒载量控制在<10 拷贝/ml,在最近的时间点控制在<200 拷贝/ml。我们比较了 15 名非控制者(NC)RMs,在血液、淋巴结(LN)和结直肠(RB)活检样本中鉴定了与 ART 后 SIV 控制相关的免疫和病毒学特征。在开始 ART 之前,与 NC 相比,PTC 具有更高的 CD4 T 细胞计数、更低的血浆病毒载量和血液及 LN 中的 SIV-DNA 含量,但具有相似的 CD8 T 细胞功能。虽然肠道 CD4 T 细胞水平相似,但 PTC 中 Th17 细胞的频率更高。在接受 ART 治疗时,PTC 血液和组织中的残留血浆病毒载量和 SIV-DNA 含量明显更低。在 ATI 后,NC 中的 SIV-DNA 含量迅速增加,而 PTC 中的 SIV-DNA 含量保持稳定甚至降低。最后,PTC 在 ATI 后表现出病毒控制的免疫益处,包括更高的 CD4 T 细胞水平和减少免疫激活。总体而言,较低的血浆病毒载量、减少的细胞相关 SIV-DNA 以及维持 Th17 稳态,包括在开始 ART 之前,是 SIV 感染的 RMs 在 ATI 后持续病毒控制的主要特征。虽然有效,但抗逆转录病毒疗法并不是 HIV 感染的治愈方法。因此,人们对在没有抗逆转录病毒治疗的情况下实现病毒缓解非常感兴趣。治疗后控制者代表了一小部分能够在停止抗逆转录病毒治疗后控制 HIV 的个体,但与这些个体相关的特征在很大程度上仅限于外周血分析。在这里,我们鉴定了 7 只感染 SIV 的恒河猴,它们与人类治疗后控制者表型相似,并对血液、淋巴结和结直肠活检样本进行了免疫和病毒学分析,以进一步了解将它们与非控制者区分开来的特征。在接受 ART 治疗之前和之后,较低的病毒载量和免疫稳态的维持,包括肠道 Th17 细胞,都被证明是实现治疗后控制的两个主要因素。总的来说,这些结果使我们对在没有抗逆转录病毒治疗的情况下实现病毒控制的重要特征有了进一步的了解。

相似文献

引用本文的文献

1
HIV controllers: hope for a functional cure.HIV 控制者:功能性治愈的希望。
Front Immunol. 2025 Feb 25;16:1540932. doi: 10.3389/fimmu.2025.1540932. eCollection 2025.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验